Together, we've treated over 15,000 patients with ICLUSIG, building experience and confidence in patients'
futures1,2
Have you considered all types of patients with CP-CML who are eligible and may benefit from treatment with
ICLUSIG?
Representative patient cases – not actual patients
Highly resistant with no mutations or history of CV events
Resistant to 1L imatinib and 2L dasatinib
Personal information
Age: 69 years
Sex: Female
Clinical background
CP-CML diagnosis: 36 months ago
Treatment history: 1L imatinib for 24 months (resistant), 2L dasatinib until 36 months (resistant)
BCR::ABL1IS level: 8%
Mutation status: No known mutation
ELTS score: Low
CV risk factors: No history of CV events
Treatment history
The most frequent mechanisms of resistance in CP-CML are BCR::ABL1-independent3
ELN CML Guidelines (2020) recommend that patients who are resistant to a 2G TKI with no mutation detected should be treated with ICLUSIG instead of another 2G TKI, unless CV risk factors preclude its use4
View this patient's full profile
Highly resistant with no history of CV events
Resistant to 1L dasatinib; T315I+
Personal information
Age: 55 years
Sex: Male
Clinical background
CP-CML diagnosis: 60 months ago
Previous treatments: 1L dasatinib for 60 months (resistant)
Mutation status: T315I+ (detected at 56 months)
BCR::ABL1IS level: 4%
ELTS score: Low
CV risk factors: Former smoker, but no history of CV events
Treatment history
ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all single BCR::ABL1 resistance mutations, including T315I1,5–7
ELN CML Guidelines (2020) note that ICLUSIG is the only TKI with activity against the T315I mutant, and recommend ICLUSIG in patients with T315I, unless CV risk factors preclude its use4
View this patient's full profile
Highly resistant with well-controlled dyslipidaemia
Resistant to 1L dasatinib; V299L+
Personal information
Age: 72 years
Sex: Female
Clinical background
CP-CML diagnosis: 48 months ago
Previous treatments: 1L dasatinib for 48 months (resistant)
Mutation status: V299L+ (detected at 48 months)
BCR::ABL1IS level: 2.8%
ELTS score: Intermediate
CV risk factors: Family history of dyslipidaemia - prescribed statins to balance lipid levels after lifestyle changes were ineffective
Treatment history
ICLUSIG, a 3G TKI, is the only UK-approved BCR::ABL1 inhibitor designed to be effective in CML patients with or without resistance mutations, including V299L4,8,9
ELN CML Guidelines (2020) recommend that patients who are resistant to a 2G TKI should be treated with ICLUSIG instead of another 2G TKI, unless CV risk factors preclude its use4
View this patient's full profile
Resistant with no history of CV events
Resistant to 1L nilotinib; E255K+
Personal information
Age: 47 years
Sex: Male
Clinical background
CP-CML diagnosis: 60 months ago
Treatment history: 1L nilotinib for 60 months (resistant)
Mutation status: E255K+ (detected at 56 months)
BCR::ABL1IS level: 2%
ELTS score: Low
CV risk factors: No history of CV events
Treatment history
ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all single BCR::ABL1 resistance mutations, including E255K1,6,7
ELN CML Guidelines (2020) recommend that patients who are resistant to a 2G TKI should be treated with ICLUSIG instead of another 2G TKI, unless CV risk factors preclude its use4
View this patient's full profile
Resistant with well-controlled hypertension and hypercholesterolaemia
Resistant to 1L imatinib and 2L dasatinib; F317L+
Hypertension may contribute to the risk of arterial occlusive events. ICLUSIG treatment should be temporarily interrupted if hypertension is not medically controlled.
Personal information
Age: 65 years
Sex: Female
Clinical background
CP-CML diagnosis: 42 months ago
Treatment history: 1L imatinib for 24 months (resistant), 2L dasatinib until 42 months (resistant)
Mutation status: F317L+ (detected at 42 months)
BCR::ABL1IS level: 1.2%
ELTS score: Intermediate
CV risk factors: well-controlled hypertension and hypercholesterolaemia
Treatment history
ICLUSIG was the first and remains the only TKI approved in Europe capable of inhibiting all single BCR::ABL1 resistance mutations, including F317L1,6,7
ELN CML Guidelines (2020) recommend that patients who are resistant to a 2G TKI should be treated with ICLUSIG instead of another 2G TKI, unless CV risk factors preclude its use4
View this patient's full profile
Adverse events should be reported. Reporting forms and information can be found at
www.hpra.ie.
Adverse events should also be reported to Incyte immediately by phoning the Toll-free phone number
1800-456-748.
You are now leaving the Incyte Iclusig website. This link will take you to a site that is not
owned or maintained by Incyte. Incyte is not responsible for the information contained on
third-party sites
You are now leaving the site www.iclusig.ie.
This link will take you to a site https://www.incyte.com, owned by Incyte Corporation and managed
by the company.